Delivering the future of intracellular medicine

Find out more Corporate Deck

Biological delivery, biologically

NanoSyrinx is a discovery stage synthetic biology company creating a next-generation platform technology for the targeted intracellular delivery of biological molecules. Most drugs do not traverse the body well, limiting their effectiveness. This is an even greater problem for biologic drugs, such as antibodies and peptides; and consequently new delivery modalities are sorely needed.

Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impossible) to drug, by enabling targeted, intracellular delivery of protein therapeutics.

Building on over a decade of fundamental research, and inspired by the unique properties of one of Nature’s own elegant solutions – a “Nanosyringe” – our team are creating a completely novel solution to the intracellular bioavailability problem.

Find out more

Newsroom

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines          

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials […]

Read more
Nature Biopharma Dealmakers figure of the NanoSyrinx platform

NanoSyrinx featured in Nature Biopharma Dealmakers

NanoSyrinx is delighted to have been featured in Nature’s Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery. The article highlights NanoSyrinx’s progress in tackling the longstanding challenge that >80% of intracellular targets remain undruggable, our platform’s ability to deliver […]

Read more
Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Join the team

NanoSyrinx is growing fast and we are seeking talented and ambitious individuals with a range of skills to join us on our journey.

Careers